Sign in

CIK 0001395937 · Large accelerated filer

Syndax Pharmaceuticals Inc

Sign in to watch
Ticker
SNDX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
320162505
Phone
781-419-1400
Business address
730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
  1. 8-K Event Executive or director change · Regulation FD disclosure
  2. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  3. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  4. 10-Q Report Quarterly Report
  5. 8-K Event Results of operations · Other events
  6. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  7. ARS Other Annual Report to Security Holders
  8. DEFA14A Proxy Proxy Materials
  9. DEF 14A Proxy Proxy Statement
  10. 4 Option exercise Chief Executive Officer acquired 6,074 shares (option exercise)
  11. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  12. 4 Planned sale Chief Executive Officer sold 7,814 shares at $15.05 ($117,564)
  13. 144 Insider Sale of Securities
  14. S-8 Other Securities Offered to Employees in Benefit Plans
  15. 10-K Report Annual Report
  16. 8-K Event Results of operations · Other events
  17. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  18. 4 Open-market sale Chief Financial Officer sold 3,777 shares at $15.50 ($58,559)
  19. 4 Open-market sale Chief Executive Officer sold 13,288 shares at $15.50 ($206,017)
  20. 4 Open-market sale President, Head of R&D sold 4,618 shares at $15.50 ($71,597)

Page 5 of 33 · 660 filings